Henry Meds: Specific Patient Profiles That Should Avoid This Platform

What Henry Meds Actually Sells

Henry Meds is a direct-to-consumer telehealth company founded around 2022. The platform primarily offers compounded semaglutide (a GLP-1 receptor agonist) and compounded tirzepatide (a dual GIP/GLP-1 agonist) at prices well below brand-name Ozempic, Wegovy, or Mounjaro.

The company operates on a subscription model. A patient completes an online intake form, a contracted clinician reviews it asynchronously, and if approved, a compounding pharmacy ships the medication directly to the patient's home. The clinician-patient relationship is largely asynchronous.

How Compounded GLP-1s Differ From Brand-Name Products

FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) undergo rigorous manufacturing quality controls, bioequivalence testing, and post-market surveillance. Compounded versions are prepared by 503A or 503B pharmacies and are explicitly not FDA-approved. The FDA does not verify that compounded drugs are safe, effective, or manufactured to the same standards as approved drugs [1].

In October 2023 and again in May 2024, the FDA issued consumer warnings specifically about compounded semaglutide, noting reports of adverse events including hospitalizations linked to dosing errors and unlicensed products [2]. The FDA removed semaglutide from its drug shortage list in March 2025, which means 503A pharmacies are no longer legally permitted to compound it for general use [3].

Business Model Considerations

Henry Meds charges patients directly. No insurance is billed, and the low price point is possible because compounded drugs carry far lower manufacturing costs than brand-name finished pharmaceuticals. The trade-off is that a patient accepts a product without FDA approval, manufactured by a third-party pharmacy whose quality controls Henry Meds does not itself certify.

The Absolute Contraindications That Apply Regardless of Platform

Before evaluating Henry Meds specifically, certain contraindications apply to all GLP-1 receptor agonists. Any platform prescribing these drugs should screen for these, and any patient with these conditions should not receive compounded or brand-name GLP-1 therapy.

Medullary Thyroid Carcinoma and MEN 2

The FDA prescribing label for semaglutide carries a Boxed Warning for thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), should never receive semaglutide or tirzepatide [4]. Rodent studies showed dose-dependent C-cell tumor formation, and while causality in humans is unproven, the risk-benefit ratio makes these absolute contraindications.

A 2023 pharmacovigilance review in JAMA Internal Medicine noted that self-reported family history screening via asynchronous online forms has a known sensitivity gap compared with in-person history-taking. An asynchronous platform cannot probe ambiguous family histories in real time.

History of Acute or Chronic Pancreatitis

GLP-1 receptor agonists have been associated with pancreatitis across multiple post-marketing datasets. The semaglutide prescribing information lists acute pancreatitis as a serious adverse reaction requiring discontinuation [4]. Patients who have had even one episode of acute pancreatitis should discuss this history with a physician capable of full clinical evaluation, not just an online form.

Severe Renal Impairment

Semaglutide causes nausea and vomiting that can produce significant dehydration. In patients with an eGFR <30 mL/min/1.73m², acute kidney injury from dehydration is a documented risk. The 2023 FLOW trial (N=3,533) showed that semaglutide 1 mg reduced kidney-disease progression in patients with type 2 diabetes and chronic kidney disease, but that benefit comes with titration and specialist oversight, not a subscription box [5].

Patient Profiles That Are Particularly Poor Candidates for Henry Meds

The following profiles represent patients where Henry Meds' business model creates specific, clinically meaningful gaps in safety. This is not a general statement about all telehealth; it reflects the specific combination of compounded (non-FDA-approved) product, asynchronous intake, and limited follow-up that characterizes this platform.

Profile 1: Patients With Complex Cardiovascular Disease

The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg and 1.0 mg reduced major adverse cardiovascular events (MACE) by 26% vs. Placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for non-inferiority) [6]. That cardiovascular benefit, however, was demonstrated with FDA-approved semaglutide doses under clinical trial monitoring, not with compounded products at titrated weight-loss doses.

Patients with recent MI (within 60 days), unstable angina, decompensated heart failure, or significant arrhythmias need their prescriber to have rapid, direct access to their cardiologist's records. A platform where clinical review is an asynchronous chart check is not designed for this coordination.

Profile 2: Patients Taking Multiple Diabetes Medications

Semaglutide and tirzepatide lower blood glucose. Patients already on sulfonylureas (glipizide, glimepiride) or insulin face a real risk of hypoglycemia when adding a GLP-1 agonist. The 2024 American Diabetes Association Standards of Care (Section 9) explicitly note that GLP-1 agonist initiation in patients on insulin secretagogues typically requires insulin dose reduction [7].

Henry Meds' intake form asks about current medications, but dose-adjustment guidance for complex insulin regimens requires active clinician involvement, not a templated response.

Profile 3: Patients With a History of Eating Disorders

GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms. In patients with a history of anorexia nervosa, bulimia, or other restrictive eating disorders, appetite suppression can reinforce disordered behaviors and trigger relapse. The American Psychiatric Association recommends psychiatric evaluation before initiating weight-loss pharmacotherapy in patients with any eating disorder history [8].

An online intake form that asks "Do you have an eating disorder?" is not a psychiatric evaluation. Nuanced histories, like a resolved diagnosis 10 years ago with occasional restrictive episodes now, require clinical conversation.

Profile 4: Patients Who Have Previously Failed or Had Adverse Reactions to GLP-1 Therapy

Prior intolerance to liraglutide, dulaglutide, or exenatide does not automatically predict intolerance to semaglutide or tirzepatide, but it should trigger a detailed review. Prior severe GI adverse events, gallstone-related complications (GLP-1 agonists increase gallstone formation rate by approximately 1.5-fold over 12 months in large cohort analyses), or injection-site reactions warrant evaluation before re-initiating a compound whose purity has not been independently verified.

Profile 5: Patients Who Cannot Self-Administer Injections or Interpret Symptoms

Compounded semaglutide and tirzepatide are typically supplied as multi-dose vials requiring the patient to draw and self-inject. This is different from the single-use pens supplied with Ozempic or Wegovy. Patients with dexterity limitations, significant visual impairment, cognitive impairment, or no reliable support person at home face higher risks of dosing error. The FDA's 2023 and 2024 safety communications specifically called out dosing errors with compounded semaglutide products, some of which led to hospitalization [2].

Profile 6: Patients With Uncontrolled Psychiatric Conditions

Weight-loss therapy often intersects with mood. Rapid weight loss and hormonal shifts can affect mood stability. Patients with bipolar I disorder, active psychosis, or poorly controlled major depressive disorder need a prescriber who can monitor these intersections. Henry Meds' model does not include integrated psychiatric monitoring.

Is Henry Meds Legit? A Regulatory and Credentialing Review

"Legit" has at least two meanings in this context: legally operating and clinically safe. The two answers are different.

Legal Operating Status

As of mid-2025, Henry Meds appears to operate through licensed telehealth clinicians and contracts with licensed compounding pharmacies. Telehealth prescribing of compounded medications is legal in most U.S. States when a valid prescriber-patient relationship exists, though the definition of that relationship varies by state. Henry Meds is not BBB-accredited, and its BBB profile includes consumer complaints primarily about billing issues and difficulty canceling subscriptions.

The more significant regulatory issue is the FDA's March 2025 removal of semaglutide from the shortage list. Under 21 U.S.C. § 503A, a 503A pharmacy may compound a drug that appears on the FDA shortage list. Once semaglutide was removed, 503A compounding became legally questionable for most use cases. 503B outsourcing facilities face similarly stricter limits. Patients starting a Henry Meds semaglutide subscription after March 2025 should confirm with the platform exactly which pharmacy is fulfilling the order, under what statutory authority, and whether that pharmacy holds a current 503B registration with the FDA [3].

LegitScript Certification

LegitScript is an FDA-recognized internet pharmacy certification body. As of this writing, Henry Meds does not hold LegitScript certification. LegitScript-certified telehealth pharmacies meet standards for prescription validity, licensed dispensing, and legal compliance. The absence of this certification is not proof of illegality, but it does mean an independent third party has not verified the platform's compliance practices.

Clinical Quality Signals

Consumer complaints on the BBB and on Reddit threads (r/Semaglutide, r/PeptidesForHealth) follow a pattern: patients report difficulty reaching a clinician after adverse events, generic responses to side-effect reports, and pressure to continue the subscription. These are anecdotal but reflect a structural issue: a platform optimized for low-cost, high-volume asynchronous prescribing has financial incentives that may not always align with conservative clinical management.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Ongoing follow-up with the prescribing clinician is necessary to monitor efficacy, adjust dosing, and identify adverse effects" [9]. A model where follow-up is primarily patient-initiated asynchronous messaging does not fully satisfy this standard for medically complex patients.

Henry Meds Complaints: Patterns Worth Noting

Documented complaint patterns do not represent all patient experiences, but they are clinically informative for risk stratification.

Billing and Cancellation Disputes

The most common Henry Meds BBB complaints involve subscription cancellation difficulties and unexpected charges. While these are administrative rather than clinical, they signal that a patient who wants to stop a medication quickly, say due to an adverse event, may face friction that delays cessation.

Side Effect Management Gaps

Several patient accounts describe reporting severe nausea, vomiting, or injection-site reactions and receiving templated responses or no clinician callback. Severe GI toxicity from semaglutide, specifically persistent vomiting causing dehydration, can escalate to acute kidney injury, particularly in patients with baseline renal vulnerability (eGFR <60 mL/min/1.73m²). Responsive clinical management in the first 4 to 8 weeks of GLP-1 titration is not optional for these patients.

Dosing Errors With Vial-Based Products

Unlike the auto-injector pens of FDA-approved branded products, compounded semaglutide typically comes as a multi-dose vial. Patients self-calculate and draw doses. The FDA's May 2024 safety communication documented cases where patients received 10x the intended dose due to unit confusion (mg vs. Units) [2]. Henry Meds provides instructional content, but the error risk is structurally higher than with a pre-filled pen.

When Henry Meds May Be Reasonable (and When It Is Not)

This is not a blanket condemnation. For a healthy adult (age 25 to 55) with BMI >30, no significant comorbidities, no relevant medical history, good health literacy, comfort with self-injection, and primary care follow-up elsewhere, the cost savings of compounded semaglutide may be acceptable if the patient understands they are using a non-FDA-approved product from a pharmacy whose quality they cannot independently verify.

The platform is a poor fit for the six profiles above and for anyone who:

• Has a first-degree relative with MTC or MEN 2
• Is pregnant, planning pregnancy within 6 months, or breastfeeding (GLP-1 agonists carry an FDA pregnancy category warning; animal data show fetal harm) [4]
• Has a BMI <27 without an obesity-related comorbidity (prescribing below labeled thresholds raises both legal and ethical concerns)
• Lives alone without a support person who can recognize signs of severe adverse events
• Lacks the financial or logistical ability to access emergency care if a serious adverse event occurs

Alternatives for Patients Who Do Not Fit the Henry Meds Profile

Patients who fall into any of the above categories have better options:

1. In-person endocrinology or obesity medicine consultation. The American Board of Obesity Medicine certifies physicians specifically in weight management. A directory is available at abom.org.

2. Telehealth platforms with synchronous clinical oversight. Platforms that require live video visits before initiating GLP-1 therapy and maintain dedicated clinical lines for adverse events offer meaningfully better safety infrastructure for medically complex patients.

3. FDA-approved branded GLP-1s with manufacturer assistance programs. Novo Nordisk and Eli Lilly both maintain savings programs that reduce out-of-pocket cost for commercially insured patients. For uninsured patients, income-based programs through the manufacturers may bring monthly costs below $100.

4. Lifestyle intervention programs with pharmacotherapy. The 2021 SCALE Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3.0 mg combined with structured lifestyle intervention produced 8.0% mean weight loss vs. 2.6% with lifestyle alone at 56 weeks [10]. Combined programs exist at many academic medical centers.